Drug profile · INN
respiratory syncytial virus mrna vaccine
MRESVIA
respiratory syncytial virus mrna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen. Associated with Teva Pharma GmbH.
EMA: approved Antiinfectives for systemic use (J07) J07BX05
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — respiratory syncytial virus mrna vaccine
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
respiratory syncytial virus mrna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen. Associated with Teva Pharma GmbH.
Key facts
INN respiratory syncytial virus mrna vaccine
Brand MRESVIA
Mechanism Fusion glycoprotein F0 vaccine antigen
Target Fusion glycoprotein F0
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BX05
Originator Teva Pharma GmbH
Mechanism of action
Fusion glycoprotein F0 vaccine antigen
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is respiratory syncytial virus mrna vaccine?
respiratory syncytial virus mrna vaccine (MRESVIA) is a fusion glycoprotein f0 vaccine antigen. Associated with Teva Pharma GmbH.
What is the brand name for respiratory syncytial virus mrna vaccine?
MRESVIA is a marketed brand name for respiratory syncytial virus mrna vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.